{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:24:47Z","timestamp":1786969487713,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cerebral Embolic Protection Devices (CEPs) have been designed to minimize the risk of periprocedural stroke. The clinical significance of these devices, however, is still under debate. We aimed to compare periprocedural neurological outcomes and mortality in patients undergoing transfemoral transcatheter aortic valve replacement (TF-TAVR) with vs. without CEP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center retrospective analysis of 1,101 patients undergoing transfemoral TAVR from August 2017 to May 2025 was performed. CEPs were used routinely at our institution whenever anatomically feasible beginning with October 2019. The primary outcome was defined as the incidence of ischemic stroke occurring within 3 days postoperatively. Secondary endpoints included transient ischemic attack (TIA) and delirium within 3 days and short-term all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 809 underwent TF-TAVR with CEP, while 292 were treated without. The primary endpoint of clinical ischemic stroke occurred less frequently in the CEP group (1.4% vs. 4.1%), and the group difference revealed a significant result in a univariable Cox regression analysis (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007). No clinically relevant differences were observed in the incidence of TIA (0.5% vs. 0.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.71) and postprocedural delirium (1.6% vs. 2.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.39). The 30-day mortality rate was numerically higher in the control group, but the difference did not reach statistical significance (1.9% vs. 3.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.06).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The use of neuroprotection during TAVR was associated with a lower observed hazard of early periprocedural ischemic stroke in this unadjusted retrospective cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1881371","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:27:41Z","timestamp":1786966061000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The association of cerebral embolic protection during transcatheter aortic valve replacement with periprocedural neurological outcomes"],"prefix":"10.3389","volume":"13","author":[{"given":"Funda","family":"Baysal","sequence":"first","affiliation":[{"name":"Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Osipenko","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severin","family":"Laengle","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Steiner","sequence":"additional","affiliation":[{"name":"Center for Medical Data Science, Institute of Medical Statistics, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amila","family":"Kahrovic","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Bartko","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zimpfer","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Andreas","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Medical University of Graz","place":["Graz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliana","family":"Coti","sequence":"additional","affiliation":[{"name":"Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100169","DOI":"10.1016\/j.shj.2023.100169","article-title":"Cerebral embolic protection in transcatheter aortic valve replacement","volume":"7","author":"Iskander","year":"2023","journal-title":"Struct Heart"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e034298","DOI":"10.1161\/JAHA.124.034298","article-title":"Outcomes and predictors of stroke after transcatheter aortic valve replacement in the cerebral protection device era","volume":"13","author":"Shekhar","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B3","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/jama.2016.10302","article-title":"Effect of a cerebral protection device on brain lesions following transcatheter aortic valve implantation in patients with severe aortic stenosis: the CLEAN-TAVI randomized clinical trial","volume":"316","author":"Haussig","year":"2016","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jacc.2016.10.023","article-title":"Protection against cerebral embolism during transcatheter aortic valve replacement","volume":"69","author":"Kapadia","year":"2017","journal-title":"JACC"},{"key":"B5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.4244\/EIJV12I4A84","article-title":"Filter-based cerebral embolic protection with transcatheter aortic valve implantation: the randomised MISTRAL-C trial","volume":"12","author":"Van Mieghem","year":"2016","journal-title":"EuroIntervention"},{"key":"B6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jcin.2020.11.011","article-title":"Randomized evaluation of TriGuard 3 cerebral embolic protection after transcatheter aortic valve replacement: REFLECT II","volume":"14","author":"Nazif","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1093\/eurheartj\/ehv191","article-title":"A prospective randomized evaluation of the TriGuard\u2122 HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial","volume":"36","author":"Lansky","year":"2015","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMoa2204961","article-title":"Cerebral embolic protection during transcatheter aortic-valve replacement","volume":"387","author":"Kapadia","year":"2022","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa2415120","article-title":"Routine cerebral embolic protection during transcatheter aortic-valve implantation","volume":"392","author":"Kharbanda","year":"2025","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/19418744231225680","article-title":"Cerebral protection in trans-catheter aortic valve replacement: review and contemporary assessment of randomized trial data","volume":"14","author":"Mehta","year":"2024","journal-title":"Neurohospitalist"},{"key":"B11","doi-asserted-by":"publisher","first-page":"7256","DOI":"10.3390\/jcm13237256","article-title":"2024 Update on cerebral embolic protection after transcatheter aortic valve replacement","volume":"13","author":"Gasior","year":"2024","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","article-title":"Transcatheter versus surgical aortic-valve replacement in high-risk patients","volume":"364","author":"Smith","year":"2011","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.4244\/eijv12i2a37","article-title":"Thirty-day outcomes in patients at intermediate risk for surgery from the SAPIEN 3 European approval trial","volume":"12","author":"Vahanian","year":"2016","journal-title":"EuroIntervention"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","article-title":"Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients","volume":"380","author":"Mack","year":"2019","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e793","DOI":"10.4244\/EIJ-D-23-01087","article-title":"Cerebrovascular events after transcatheter aortic valve implantation","volume":"20","author":"Reddy","year":"2024","journal-title":"EuroIntervention"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6754","DOI":"10.3390\/jcm14196754","article-title":"Stroke in transcatheter aortic valve implantation (TAVI): a comprehensive review","volume":"14","author":"Nikas","year":"2025","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2019.7525","article-title":"Association between transcatheter aortic valve replacement and early postprocedural stroke","volume":"321","author":"Huded","year":"2019","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/CIRCULATIONAHA.112.001091","article-title":"Histopathology of embolic debris captured during transcatheter aortic valve replacement","volume":"127","author":"Van Mieghem","year":"2013","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4244\/EIJ-D-23-00166","article-title":"Cerebral embolic protection during transcatheter heart interventions","volume":"19","author":"Jimenez Diaz","year":"2023","journal-title":"EuroIntervention"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/eurheartj\/ehab002","article-title":"Silent brain infarcts and early cognitive outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis","volume":"42","author":"Woldendorp","year":"2021","journal-title":"Eur Heart J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jacc.2024.05.055","article-title":"Clinical significance of diffusion-weighted brain MRI lesions after TAVR: results of a patient-level pooled analysis","volume":"84","author":"Lansky","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1001\/jamacardio.2024.4278","article-title":"Cerebral embolic protection by geographic region: a post hoc analysis of the PROTECTED TAVR randomized clinical trial","volume":"10","author":"Makkar","year":"2025","journal-title":"JAMA Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1161\/circulationaha.125.076761","article-title":"Impact of cerebral embolic protection on cognitive function after transcatheter aortic valve implantation: data from the BHF PROTECT-TAVI randomized trial","volume":"152","author":"Kennedy","year":"2025","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12872-023-03338-0","article-title":"Cerebral embolic protection during transcatheter aortic valve replacement: a systematic review and meta-analysis of propensity score matched and randomized controlled trials using the sentinel cerebral embolic protection device","volume":"23","author":"Wolfrum","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1016\/j.jcin.2017.06.037","article-title":"Cerebral embolic protection during transcatheter aortic valve replacement significantly reduces death and stroke compared with unprotected procedures","volume":"10","author":"Seeger","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1002\/ccd.70146","article-title":"Efficacy of cerebral embolic protection device in transcatheter aortic valve replacement: a systematic review and meta-analysis","volume":"106","author":"Shahid","year":"2025","journal-title":"Catheter Cardiovasc Interv"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14779072.2024.2445256","article-title":"Safety and efficacy of cerebral embolic protection systems in transcatheter aortic valve replacement: a systematic review and meta-analysis","volume":"22","author":"Kheyrbek","year":"2024","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4244\/EIJV8I1A20","article-title":"Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients","volume":"8","author":"Eggebrecht","year":"2012","journal-title":"EuroIntervention"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e007605","DOI":"10.1161\/circinterventions.118.007605","article-title":"Early clinical impact of cerebral embolic protection in patients undergoing transcatheter aortic valve replacement","volume":"12","author":"Kroon","year":"2019","journal-title":"Circ Cardiovasc Interv"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1881371\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:27:41Z","timestamp":1786966061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1881371\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":29,"alternative-id":["10.3389\/fcvm.2026.1881371"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1881371","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1881371"}}